| | Entecavir Better Than Lamivudine In Chronically Infected Hepatitis B Patients (Site not responding. Last check: 2007-10-17) |
 | | Safety was comparable between the treatment groups, with similar incidence of serious adverse events (6 percent with entecavir, 8 percent with lamivudine) and total adverse events (75 percent with entecavir, 79 percent with lamivudine). |
 | | ALT level elevations were observed in 3 percent of patients on treatment receiving entecavir compared to 5 percent on treatment receiving lamivudine and in 14 percent versus 22 percent of patients off treatment, respectively. |
 | | Safety was comparable between the treatment groups, with similar incidence of serious adverse events (10 percent with entecavir, 8 percent with lamivudine) and total adverse events (85 percent with entecavir, 81 percent with lamivudine). |
| www.pharma-lexicon.com /medicalnews.php?newsid=15698 (1072 words) |